Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: Cobomarsen Extension for CTCL/MF
NCT03837457Phase 2Terminated
- Sponsor
- Viridian Therapeutics
- Start
- Oct 2019
- Primary completion
- Jul 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of cobomarsen in mycosis fungoides (MF), sponsored by Viridian Therapeutics. Primary endpoint: Objective Response Rate of at least 4 months duration. Started Oct 2019; status: terminated.
02
Drugs
cobomarsen
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03837457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837457.